Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/APP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/APP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/APP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/APP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/APP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/APP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/APP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/APP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/APP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/APP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/APP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009314110 | Skin | SCCIS | response to radiation | 50/919 | 456/18723 | 9.08e-08 | 1.27e-05 | 50 |
GO:0007568110 | Skin | SCCIS | aging | 41/919 | 339/18723 | 9.54e-08 | 1.29e-05 | 41 |
GO:0045862112 | Skin | SCCIS | positive regulation of proteolysis | 43/919 | 372/18723 | 1.69e-07 | 1.91e-05 | 43 |
GO:006156417 | Skin | SCCIS | axon development | 49/919 | 467/18723 | 4.63e-07 | 3.77e-05 | 49 |
GO:000268517 | Skin | SCCIS | regulation of leukocyte migration | 29/919 | 210/18723 | 4.69e-07 | 3.77e-05 | 29 |
GO:0045861112 | Skin | SCCIS | negative regulation of proteolysis | 40/919 | 351/18723 | 6.58e-07 | 5.13e-05 | 40 |
GO:000268717 | Skin | SCCIS | positive regulation of leukocyte migration | 22/919 | 135/18723 | 6.75e-07 | 5.19e-05 | 22 |
GO:0051403110 | Skin | SCCIS | stress-activated MAPK cascade | 31/919 | 239/18723 | 7.71e-07 | 5.68e-05 | 31 |
GO:0016049111 | Skin | SCCIS | cell growth | 49/919 | 482/18723 | 1.17e-06 | 7.78e-05 | 49 |
GO:000257319 | Skin | SCCIS | myeloid leukocyte differentiation | 28/919 | 208/18723 | 1.24e-06 | 8.07e-05 | 28 |
GO:0031098110 | Skin | SCCIS | stress-activated protein kinase signaling cascade | 31/919 | 247/18723 | 1.57e-06 | 9.08e-05 | 31 |
GO:000740917 | Skin | SCCIS | axonogenesis | 44/919 | 418/18723 | 1.63e-06 | 9.13e-05 | 44 |
GO:0009896112 | Skin | SCCIS | positive regulation of catabolic process | 49/919 | 492/18723 | 2.10e-06 | 1.09e-04 | 49 |
GO:0030099112 | Skin | SCCIS | myeloid cell differentiation | 41/919 | 381/18723 | 2.11e-06 | 1.09e-04 | 41 |
GO:003287219 | Skin | SCCIS | regulation of stress-activated MAPK cascade | 26/919 | 192/18723 | 2.64e-06 | 1.28e-04 | 26 |
GO:007030219 | Skin | SCCIS | regulation of stress-activated protein kinase signaling cascade | 26/919 | 195/18723 | 3.53e-06 | 1.62e-04 | 26 |
GO:0006979112 | Skin | SCCIS | response to oxidative stress | 45/919 | 446/18723 | 3.89e-06 | 1.76e-04 | 45 |
GO:0052547112 | Skin | SCCIS | regulation of peptidase activity | 46/919 | 461/18723 | 4.09e-06 | 1.82e-04 | 46 |
GO:0051099112 | Skin | SCCIS | positive regulation of binding | 24/919 | 173/18723 | 4.14e-06 | 1.82e-04 | 24 |
GO:000725417 | Skin | SCCIS | JNK cascade | 23/919 | 167/18723 | 7.39e-06 | 2.80e-04 | 23 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501023 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501033 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
hsa0502233 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501044 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa0501054 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa050102 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
hsa050222 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
hsa050103 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
hsa050223 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APP | SNV | Missense_Mutation | novel | c.1701G>C | p.Gln567His | p.Q567H | P05067 | protein_coding | tolerated(0.1) | possibly_damaging(0.906) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
APP | SNV | Missense_Mutation | rs201093867 | c.710N>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
APP | SNV | Missense_Mutation | | c.533A>G | p.Lys178Arg | p.K178R | P05067 | protein_coding | tolerated(1) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | | c.853G>C | p.Glu285Gln | p.E285Q | P05067 | protein_coding | tolerated(0.17) | benign(0.403) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
APP | SNV | Missense_Mutation | rs199549173 | c.1406N>A | p.Arg469His | p.R469H | P05067 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs760615902 | c.1666N>A | p.Glu556Lys | p.E556K | P05067 | protein_coding | deleterious(0.01) | benign(0.132) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs200521782 | c.1690G>C | p.Glu564Gln | p.E564Q | P05067 | protein_coding | deleterious(0.01) | possibly_damaging(0.757) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
APP | SNV | Missense_Mutation | rs201093867 | c.710T>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | | c.124N>C | p.Asn42His | p.N42H | P05067 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs201093867 | c.710T>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | GENTIAN VIOLET | GENTIAN VIOLET | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | ALZ-801 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Affitope AD-01 | | 22506132 |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | AAB-003/PF-05236812 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | CHEMBL2109300 | GSK933776 | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | MABT5102A | CRENEZUMAB | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | MER-5101 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | AAB-002 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Gantenerumab | GANTENERUMAB | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Systebryl | | |